Activation of the adrenocortical axis by surgical stress: involvement of central norepinephrine and interleukin-1.
In the present study, we examined the mechanisms involved in the activation of the adrenocortical axis following surgical stress. Adult male rats underwent surgical laparotomy or craniotomy under ether anesthesia while control rats were only ether-anesthetized. Four hours following laparotomy or craniotomy, serum adrenocorticotropin (ACTH) and corticosterone (CS) were significantly increased and returned to almost basal levels after 24 h. Laparotomy also caused a significant depletion of corticotropin-releasing hormone (CRH-41) in the median eminence (ME). Pretreatment with dexamethasone 50 microg/kg completely abolished the pituitary-adrenal response while pretreatment with type II corticosteroid receptor antagonist caused a significant hypersecretion of both ACTH and CS and inhibited the effect of dexamethasone. The response to laparotomy was markedly attenuated in rats injected with 6-hydroxydopamine into the paraventricular nucleus (PVN) which significantly depletes norepinephrine (NE) PVN content. Intracerebroventricular injection of interleukin-1 receptor antagonist (IL-1ra) also inhibited the pituitary-adrenal response to laparotomy. The results suggest that (1) surgical stress activates the hypothalamo-pituitary-adrenal (HPA) axis via a mechanism which involves the release of CRH from the ME and NE input to the PVN; (2) the adrenocortical response is sensitive to the negative feedback of glucocorticoids via the mediation of type II glucocorticoid receptors, and (3) central IL-1 may be a mediator in the HPA axis response to surgical stress.
DeKeyser
F G
FG
School of Nursing, Hadassah University Hospital, Hebrew University-Hadassah Medical School, Jerusalem, Israel. Freda@md2.huji.ac.il
Leker
R R
RR
Weidenfeld
J
J
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D003399:Craniotomy; D006727:Hormone Antagonists / Q000008:administration & dosage; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000502:physiology*; D007813:Laparotomy; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D015735:Mifepristone / Q000008:administration & dosage; D009638:Norepinephrine / Q000502:physiology*; D016627:Oxidopamine / Q000008:administration & dosage; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D013312:Stress, Physiological / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*
D006727:Hormone Antagonists; D007375:Interleukin-1; D015735:Mifepristone; D016627:Oxidopamine; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone; D009638:Norepinephrine